Osteogenic graft vascularization and bone resorption by VEGF-expressing human mesenchymal progenitors


Helmrich U., Di Maggio N., Gueven S., Groppa E., Melly L., Largo R. D., ...More

BIOMATERIALS, vol.34, no.21, pp.5025-5035, 2013 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 21
  • Publication Date: 2013
  • Doi Number: 10.1016/j.biomaterials.2013.03.040
  • Journal Name: BIOMATERIALS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.5025-5035
  • Keywords: Angiogenesis, Bone tissue engineering, Mesenchymal stem cell, Osteoclast, Silicate-substituted apatite, VEGF
  • Dokuz Eylül University Affiliated: No

Abstract

Rapid vascularisation of tissue-engineered osteogenic grafts is a major obstacle in the development of regenerative medicine approaches for bone repair. Vascular endothelial growth factor (VEGF) is the master regulator of vascular growth. We investigated a cell-based gene therapy approach to generate osteogenic grafts with an increased vascularization potential in an ectopic nude rat model in vivo, by genetically modifying human bone marrow-derived stromal/stem cells (BMSC) to express rat VEGF. BMSC were loaded onto silicate-substituted apatite granules, which are a clinically established osteoconductive material. Eight weeks after implantation, the vascular density of constructs seeded with VEGF-BMSC was 3-fold greater than with control cells, consisting of physiologically structured vascular networks with both conductance vessels and capillaries. However, VEGF specifically caused a global reduction in bone quantity, which consisted of thin trabeculae of immature matrix. VEGF did not impair BMSC engraftment in vivo, but strongly increased the recruitment of TRAP- and Cathepsin K-positive osteoclasts. These data suggest that VEGF over-expression is effective to improve the vascularization of osteogenic grafts, but also has the potential to disrupt bone homoeostasis towards excessive degradation, posing a challenge to its clinical application in bone tissue engineering. (C) 2013 Elsevier Ltd. All rights reserved.